http://orcid.org/0000-0003-1436-5089
References
- Committee on a National Strategy for the Elimination of Hepatitis B and C. Board on population health and public health practice, health and medicine division, National Academies of Sciences, Engineering, and Medicine. In: Buckley GJ, Strom BL, editors. Eliminating the public health problem of Hepatitis B and C in the United States: phase one report. Washington (DC): National Academies Press (US); 2016 Jun 1. PubMed PMID: 27336113.
- Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–2617.
- Feld JJ, Jacobson IM, Hézode C, et al. ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–2607.
- Cenderello G, Artioli S, Viscoli C, et al. Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation. Clinicoecon Outcomes Res. 2015;8:15–21.
- Garagiola E, Ferrario L, Croce D, et al. HCV novel therapeutic regimens in wonderland: a budget impact analysis in the Lombardy Region. Dig Liver Dis. 2016;48(10):1200–1207.
- Fraccaro P, Pupella V, Gazzarata R, et al. The ligurian human immunodeficiency virus clinical network: a web tool to manage patients with human immunodeficiency virus in primary care and multicenter clinical trials. Med 2 0. 2013;2(2):e5.
- Cenderello G, Fanizza C, Marenco S, et al. Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis. Clinicoecon Outcomes Res. 2017;9:281–293.
- Determina AIFA n. 500/2017 pubblicata nella G.U. n. 75 del 30/03/2017. Accessed 18 October 2018 http://www.aifa.gov.it/content/aggiornamento-epatite-c
- Wolston S, Kim N Accessed 18 October 2018 https://www.hepatitisc.uw.edu/go/evaluation-treatment/cost-access-medications/core-concept/all.
- National Institute for Health and Care Excellence (NICE). Sofosbuvir–velpatasvir for treating chronic hepatitis C. Accessed 18 October 2018. https://www.nice.org.uk/guidance/TA430/chapter/1-Recommendations
- Deuffic-Burban S, Huneau A, Verleene A, et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018;69:785–792.
- Taramasso L, Demma F, Bitonti R, et al. How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy. BMC Health Serv Res. 2018;18:691.
- Abozeid M, Alsebaey A, Abdelsameea E, et al. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. Int J Infect Dis. 2018;75:109–114.
- Heath K. Cost effectiveness analysis of treatment timing considering the future entry of lower cost generics for hepatitis C. Clinicoecon Outcomes Res. 2018;10:539–550.
- European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. 2018. J Hepatol. 2018;69(2):461–511. doi:10.1016/j.jhep.2018.03.026. Epub 2018 Apr 9. PubMed PMID: 29650333.